Bionano Laboratories announced the expansion of its clinical testing menu with the launch of two new laboratory developed tests, LDTs, based on optical genome mapping, OGM, OGM-DxTM Postnatal Whole Genome SV and OGM-DxTM Prenatal Whole Genome SV. These LDTs offer a genome-wide assessment of structural variants, SVs, and provide comprehensive testing for most common and rare chromosomal abnormalities. "We are pleased to see the launch of Bionano Laboratories’ LDTs for postnatal and prenatal analysis, which can assist patients in their diagnostic and prognostic journey. These LDTs are designed to provide a comprehensive evaluation of genome wide SVs that we believe will assist clinicians in assessing the best potential medical management for their patients," stated Justin Leighton, vice president of laboratory business at Bionano Laboratories.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BNGO:
- Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) Annual Meeting Featuring OGM Utility Across a Broad Range of Research Applications
- Bionano Genomics sees FY23 revenue $35M-$38M, consensus $39.62M
- Bionano Genomics reports Q4 revenue $8.21M , consensus $8M
- Bionano Genomics options imply 14.3% move in share price post-earnings
- Bionano Genomics announces publication of results from OGM trial